This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Immune cell regulation company MiroBio relocates to The Oxford Science Park

Immune cell regulation company MiroBio relocates to The Oxford Science Park

01 Jul 2020

Oxford, UK, 1 July 2020 – The community of innovative companies at The Oxford Science Park, one of the UK’s leading parks for science and technology companies, is being enhanced by the addition of MiroBio, a novel therapeutics company based on insights into the regulation of receptor signalling in immune cells. MiroBio, which launched in October last year with a  £27m Series A round, is taking laboratory and office space at the Park as it... Read more

EVOX THERAPEUTICS ANNOUNCES MULTI-TARGET RNA INTERFERENCE & ANTISENSE RESEARCH COLLABORATION/LICENSE AGREEMENT WITH LILLY

EVOX THERAPEUTICS ANNOUNCES MULTI-TARGET RNA INTERFERENCE & ANTISENSE RESEARCH COLLABORATION/LICENSE AGREEMENT WITH LILLY

09 Jun 2020

Evox to use its proprietary exosome loading and CNS-targeting technologies to develop oligonucleotide drugs for the treatment of neurological disorders Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, is pleased to announce a research collaboration and license agreement with Eli Lilly and Company to leverage Evox’s proprietary DeliverEXTM platform to develop and deliver RNA interference... Read more

BERGENBIO CONFIRMS FIRST COVID19 PATIENT DOSED WITH BEMCENTINIB IN ACCORD TRIAL

BERGENBIO CONFIRMS FIRST COVID19 PATIENT DOSED WITH BEMCENTINIB IN ACCORD TRIAL

02 Jun 2020

Bergen, Norway – 02 June 2020: BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces that dosing has commenced in the UK Government-backed Phase II clinical trial assessing bemcentinib in hospitalised COVID-19 patients. Bemcentinib was selected as the first candidate to be tested as part of... Read more

Immunocore announces dosing of first patient with fourth ImmTAC

Immunocore announces dosing of first patient with fourth ImmTAC

26 May 2020

IMC-F106C studied for the treatment of advanced cancers that express PRAME (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 26 May 2020) Immunocore(or the “Company”), a pioneering, clinical-stage T cell receptor biotechnology company working to develop and commercialise a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease, today announces the start of the... Read more

Exscientia raises $60 million in Series C financing round led by Novo Holdings

Exscientia raises $60 million in Series C financing round led by Novo Holdings

26 May 2020

26th May 2020, Oxford, Copenhagen, and Hamburg – Exscientia, the world leading artificial intelligence (AI) drug discovery company, today announced it has raised $60 million in a Series C financing round. The financing round has been led by new investor Novo Holdings with existing investors – Evotec, Bristol Myers Squibb, and GT Healthcare Capital (through its LPs) – participating in the round. Robert Ghenchev, Senior Partner and Head of... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More